Multicenter Pilot Study of BB3 to Improve Renal Function in Patients With Signs and Symptoms of Significant Renal Injury After Kidney Transplantation and at Risk for Dialysis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 May 2015
Price : $35 *
At a glance
- Drugs ANG 3777 (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Sponsors Angion Biomedica
- 04 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
- 04 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 06 Oct 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2014 to 1 Apr 2015.